Docetaxel (Taxotere®) in the treatment of prostate cancer

Tomasz (Tom) Beer, Mohammed El-Geneidi, Kristine M. Eilers

    Research output: Contribution to journalArticle

    36 Citations (Scopus)

    Abstract

    Docetaxel (Taxotere®) is a taxoid derived from the needles of the European yew tree, Taxus baccata. With an overall prostate-specific antigen response rate of 42% in four Phase II studies, docetaxel has important single-agent activity in androgen-independent prostate cancer. Phase II studies suggest that the addition of estramustine (Emcyt®) to docetaxel results in higher response rates but also increased toxicity. Docetaxel with and without estramustine is being evaluated in Phase III studies that will provide definitive information about its role in androgen-independent prostate cancer. Novel combinations of docetaxel with biologic response modifiers are in early stages of development. Similarly, a number of investigators are conducting exploratory trials that incorporate docetaxel into multimodality approaches to high-risk localized prostate cancer treatment.

    Original languageEnglish (US)
    Pages (from-to)261-268
    Number of pages8
    JournalExpert Review of Anticancer Therapy
    Volume3
    Issue number3
    StatePublished - Jun 2003

    Fingerprint

    docetaxel
    Prostatic Neoplasms
    Estramustine
    Androgens
    Taxus
    Taxoids
    Prostate-Specific Antigen
    Needles

    Keywords

    • Chemoteraphy
    • Docetaxel
    • Prostate cancer

    ASJC Scopus subject areas

    • Pharmacology
    • Cancer Research

    Cite this

    Docetaxel (Taxotere®) in the treatment of prostate cancer. / Beer, Tomasz (Tom); El-Geneidi, Mohammed; Eilers, Kristine M.

    In: Expert Review of Anticancer Therapy, Vol. 3, No. 3, 06.2003, p. 261-268.

    Research output: Contribution to journalArticle

    Beer, TT, El-Geneidi, M & Eilers, KM 2003, 'Docetaxel (Taxotere®) in the treatment of prostate cancer', Expert Review of Anticancer Therapy, vol. 3, no. 3, pp. 261-268.
    Beer, Tomasz (Tom) ; El-Geneidi, Mohammed ; Eilers, Kristine M. / Docetaxel (Taxotere®) in the treatment of prostate cancer. In: Expert Review of Anticancer Therapy. 2003 ; Vol. 3, No. 3. pp. 261-268.
    @article{e6a5b65c9efb402494aec8df5064c4c1,
    title = "Docetaxel (Taxotere{\circledR}) in the treatment of prostate cancer",
    abstract = "Docetaxel (Taxotere{\circledR}) is a taxoid derived from the needles of the European yew tree, Taxus baccata. With an overall prostate-specific antigen response rate of 42{\%} in four Phase II studies, docetaxel has important single-agent activity in androgen-independent prostate cancer. Phase II studies suggest that the addition of estramustine (Emcyt{\circledR}) to docetaxel results in higher response rates but also increased toxicity. Docetaxel with and without estramustine is being evaluated in Phase III studies that will provide definitive information about its role in androgen-independent prostate cancer. Novel combinations of docetaxel with biologic response modifiers are in early stages of development. Similarly, a number of investigators are conducting exploratory trials that incorporate docetaxel into multimodality approaches to high-risk localized prostate cancer treatment.",
    keywords = "Chemoteraphy, Docetaxel, Prostate cancer",
    author = "Beer, {Tomasz (Tom)} and Mohammed El-Geneidi and Eilers, {Kristine M.}",
    year = "2003",
    month = "6",
    language = "English (US)",
    volume = "3",
    pages = "261--268",
    journal = "Expert Review of Anticancer Therapy",
    issn = "1473-7140",
    publisher = "Expert Reviews Ltd.",
    number = "3",

    }

    TY - JOUR

    T1 - Docetaxel (Taxotere®) in the treatment of prostate cancer

    AU - Beer, Tomasz (Tom)

    AU - El-Geneidi, Mohammed

    AU - Eilers, Kristine M.

    PY - 2003/6

    Y1 - 2003/6

    N2 - Docetaxel (Taxotere®) is a taxoid derived from the needles of the European yew tree, Taxus baccata. With an overall prostate-specific antigen response rate of 42% in four Phase II studies, docetaxel has important single-agent activity in androgen-independent prostate cancer. Phase II studies suggest that the addition of estramustine (Emcyt®) to docetaxel results in higher response rates but also increased toxicity. Docetaxel with and without estramustine is being evaluated in Phase III studies that will provide definitive information about its role in androgen-independent prostate cancer. Novel combinations of docetaxel with biologic response modifiers are in early stages of development. Similarly, a number of investigators are conducting exploratory trials that incorporate docetaxel into multimodality approaches to high-risk localized prostate cancer treatment.

    AB - Docetaxel (Taxotere®) is a taxoid derived from the needles of the European yew tree, Taxus baccata. With an overall prostate-specific antigen response rate of 42% in four Phase II studies, docetaxel has important single-agent activity in androgen-independent prostate cancer. Phase II studies suggest that the addition of estramustine (Emcyt®) to docetaxel results in higher response rates but also increased toxicity. Docetaxel with and without estramustine is being evaluated in Phase III studies that will provide definitive information about its role in androgen-independent prostate cancer. Novel combinations of docetaxel with biologic response modifiers are in early stages of development. Similarly, a number of investigators are conducting exploratory trials that incorporate docetaxel into multimodality approaches to high-risk localized prostate cancer treatment.

    KW - Chemoteraphy

    KW - Docetaxel

    KW - Prostate cancer

    UR - http://www.scopus.com/inward/record.url?scp=0037869481&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0037869481&partnerID=8YFLogxK

    M3 - Article

    VL - 3

    SP - 261

    EP - 268

    JO - Expert Review of Anticancer Therapy

    JF - Expert Review of Anticancer Therapy

    SN - 1473-7140

    IS - 3

    ER -